Clinical Trial Update: Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial assessing ocular tolerance, safety, and ocular pharmacokinetics after a single drop of T1225 at 0.5%, 1.0%, or 1.5% in 48 healthy volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Conjunctivitis

Drugs mentioned

• T1225

Snippet

Sponsor: Laboratoires Thea | Conditions: Eye Infections, Bacterial | Phase 1 | Status: COMPLETED